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The renin-angiotensin system (RAS) is up-regulated in patients with colorectal cancer (CRC) and is reported to be 
associated with poor prognosis and chemo-resistance. Here we explored the therapeutic potential of targeting RAS 
in CRC using Losartan, an angiotensin receptor blocker. An integrative-systems biology approach was used to 
explore a proteome-level dataset of a gene signature that is modulated by Losartan. The anti-proliferative activity 
of Losartan was evaluated using 2- and 3-dimensional cell culture models. A xenograft model of colon cancer was 
used to investigate tumor growth with Losartan alone and in combination with 5-FU followed by histological 
staining (Hematoxylin & Eosin and Masson trichrome staining), biochemical analyses, gene expression analyses 
by RT-PCR, western blot/IHC, or MMP Gelatin Zymography studies. Effects on cell cycle and cell death were 
assessed by flow cytometry. Losartan inhibited cell growth and suppressed cell cycle progression, causing an 
increase in CRC cells in the G1 phase. Losartan significantly reduced tumor growth and enhanced tumor cell 
necrosis. An impact on the inflammatory response, including up-regulation of pro-inflammatory cytokines and 
chemokines in CRC cells are potential mechanisms that could partially explain Losartan’s anti-proliferative ef-
fects. Moreover, metastasis and angiogenesis were reduced in Losartan-treated mice as observed by inhibited ma-
trix metalloproteinase-2 and -9 activities and decreased tumor vasculature. These data demonstrate the therapeutic 
potential of combining chemotherapeutic regimens with Losartan to synergistically enhance its activity and target 
the renin-angiotensin system as a new approach in colorectal cancer treatment. 
 




Colorectal cancer (CRC) is the third most 
common cancer and the fourth most common 
cause of cancer–related death globally 
(Marjaneh et al., 2018). Inflammatory and he-
reditary diseases such as personal/family his-
tory of adenoma polyps and colorectal cancer, 
inflammatory bowel disease and ulcerative 
colitis, as well as life style, are associated with 
increased risk of colon cancer (Haggar and 
Boushey, 2009). Progress in screening meth-
ods and introduction of novel specific inhibi-
tors in the past decade incidence have de-
creased the mortality rate of CRC (Torre et 
al., 2015). However, in metastatic CRC, the 
risk of recurrence remains a challenge in the 
clinical setting and finding an effective treat-
ment is urgently needed. In the meantime, 
currently approved drugs may have undiscov-
ered therapeutic properties and can be repur-
posed as adjunctive therapies to increase effi-
cacy of current chemotherapies. For instance, 
several studies have shown that renin-angio-
tensin system inhibitors (RASIs) currently 
used as anti-hypertensive and renal protective 
medications may also exert anti-tumor activi-
ties (Neo et al., 2007; Ahmadian et al., 2018a; 
Liang et al., 2008).  
Whilst the renin-angiotensin system is 
mainly involved in the regulation of blood 
pressure and body fluid balance (Ager et al., 
2008), there are several studies showing that 
renin-angiotensin system also regulate differ-
ent aspects of tumor progression, including: 
cell proliferation, angiogenesis, inflamma-
tion, and apoptosis (Deshayes and Nahmias, 
2005). Angiotensin converting enzyme 
(ACE) is one of the key enzymes in the renin-
angiotensin system, converting angiotensin I 
to angiotensin II (Smith and Missailidis, 
2004). Angiotensin II is postulated to elicit tu-
morigenic effects by binding mainly angio-
tensin II receptor type I (ATR1) and angioten-
sin II receptor type II (ATRII) (Ager et al., 
2008). Interestingly, it has been shown that 
ACE inhibitors (ACEI) or Angiotensin II Re-
ceptor Blockers (ARBs) decrease tumor pro-
gression in several types of cancers. In sup-
port of these findings, it has been demon-
strated that administration of ACEI or angio-
tensin II receptor blockers ARBs, reduce tu-
mor burden, volume, and angiogenesis, and 
increase tumor apoptosis of CRC liver metas-
tasis in a murine model (Neo et al., 2007; Koh 
et al., 2014). It has also been shown that ex-
posure to ACEI and ARBs decrease tumor 
progression and hospitalization and increase 
survival in patients with advanced colon can-
cer (Engineer et al., 2013). Thus, a greater un-
derstanding of the cytotoxic effects of Losar-
tan on cancer cells may lead to novel and clin-
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ically beneficial applications of this potent an-
giotensin receptor antagonist in combination 
with chemotherapies in the clinic. 
Here we have investigated the therapeutic 
potential and the molecular mechanism of 
Losartan in CRC progression by using a cel-
lular system, animal model, and genome-wide 
alterations in the cellular pathways based on 
high throughput data deposited in the iLINCS 
(integrative Library of Integrated Network-
Based Cellular Signatures) database for a bet-
ter understanding and hence a better manage-
ment of the disease. 
 
MATERIALS AND METHODS 
Drugs and chemicals 
Losartan and Fluorouracil (5-FU) were 
obtained from Sigma-Aldrich (Zwijndrecht, 
The Netherlands). F12/Dulbecco’s Modified 
Eagle Medium (DMEM/F12), fetal bovine se-
rum (FBS), penicillin and streptomycin were 
purchased from Gibco BRL, Life Technolo-
gies Inc. (Gaithersburg, MD, USA). Antibod-
ies for phospho-AKT (Thr 308), PI3K (p110 
α), and β-actin were obtained from Cell Sig-
naling Technology (Beverly, MA, USA). Pri-
mary Cyclin D1 and secondary antibodies 
were purchased from Santa Cruz Biotechnol-
ogy (Santa Cruz, CA, USA).  
 
Systems analysis of Losartan effect on  
cellular pathways 
The iLINCS database 
(http://www.ilincs.org/ilincs/) was used to ex-
tract the gene signature of 1-100 µM Losartan 
assessed on HT-29 colon cancer cell line da-
tasets after 24 hour incubation with the drug 
(LINCSCP _126360, LINCSCP_126358, 
LINCSCP). Significantly up or down regu-
lated genes were selected (Adjusted p-value < 
0.05 and - 0.2 < log (expression) < 0.2). Genes 
were then submitted to the Enrichr database 
(http://amp.pharm.mssm.edu/Enrichr/) for 
pathway analysis (Kuleshov et al., 2016). 
WikiPathways library was used as reference 
for pathways. An adjusted p-value of < 0.05 
was chosen for identifying pathways for fur-
ther analysis. The gene content of selected 
pathways was used in STRING v.10.5 for 
analysis of protein-protein interactions 
(Szklarczyk et al., 2015). Interactions defined 
by text-mining were excluded and the result-
ing network was visualized with Gephi 0.8.2. 
Expression data related to the genes within se-
lected pathways were presented as a heatmap 
using pheatmap package in R software. 
Cell culture 
CT-26 cell line was obtained from the 
Pasteur Institute (Tehran, Iran) and main-
tained at 37 °C in 5 % CO2 in DMEM/F12 
medium supplemented with 10 % heat-inacti-
vated FBS and 0.1 % penicillin-streptomycin. 
Cell viability (MTT) assay 
MTT assay was used to determine cyto-
toxicity of different concentrations of Losar-
tan (0-1000 μM) on CRC cells as previously 
described (Amerizadeh et al., 2018). 
 
Multicellular spheroids 
Spheroids were developed by seeding 105 
cells in RMPI/F12+GlutaMAX-I (1:1) into 
agarose coated 96-well plates. The spheroid 
formation, growth and Losartan cytotoxic ef-
fects were assessed over 7 days under an in-
verted phase contrast microscope Leica-
DMI300B (Leica, Wetzlar, Germany). Sphe-
roid volume (V) was calculated from the geo-
metric mean of the perpendicular diameters 
D= (Dmax+Dmin)/2 as follows: V= (4/3) ×π 
(D/2)3. 
 
Cell cycle analysis 
Flow cytometry was used for cell cycle 
analysis as described previously (Marjaneh et 
al., 2018). Briefly, following treatment of 
CT26 cells with Losartan (300 and 500 nM) 
for 24 h, cells were exposed to propidium io-
dide (PI) and the cell cycle was analyzed us-
ing a FACSCalibur flow cytometer (BD Bio-
sciences).  
 
MMP gelatin zymography 
The enzymatic activities of matrix metal-
loproteinases (MMP)-2 and -9 were studied 
using gelatin zymography as described previ-
ously (Bai et al., 2013). Briefly, CT-26 cells 
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were exposed to Losartan (300 nM) at differ-
ent time points. The cell culture medium was 
collected and proteins at the same concentra-
tions were electrophoresed on 10 % poly-
acrylamide zymogram gel containing 0.1 % 
gelatin. Following electrophoresis, the gels 
were subjected to a renaturation step over-
night at 37 °C. Proteinase activities appeared 
as clear bands after Coomassie blue R-250 
staining and de-staining. The intensity of 
bands was quantified using ImageJ software. 
 
Quantitative Real-Time Polymerase- 
Chain-Reaction (qRT-PCR) 
mRNAs were extracted from CT-26 cells 
or CRC tissues and complementary DNAs 
(cDNA) synthesized as described (Dinarvand 
et al., 2015; Hassanian et al., 2014). The real-
time PCR amplification was carried out using 
specific primers for target genes (Macrogene, 
Seoul, Korea) (Table 1) by light cycler Real-
time PCR (Roche Diagnostics, Mannheim, 
Germany). Glyceraldehyde 3-phosphate de-
hydrogenase (GAPDH) was used as a house-
keeping control gene.  
 
Western blotting 
Western blotting was performed as de-
scribed (Hassanian et al., 2015, 2016). 
Briefly, total protein of colon cancer tissues 
was extracted and equal amount of protein 
was electrophoresed on sodium dodecyl sul-
fate polyacrylamide gels (SDS-PAGE) and 
transferred to nitrocellulose membranes. Fol-
lowing blocking, membranes were incubated 
with different antibodies and bands were vis-
ualized using chemiluminescence substrates. 
 
Animal experiment 
BALB/c mice were obtained from Pasteur 
Institute (Tehran, Iran) between 6–8 weeks 
old. Two weeks after implantation of tumor 
cells, when the tumor volume reached 80-
100 mm3, mice were divided into 4 groups. 
Untreated mice were placed into group 1 as a 
control, group 2 received 5 mg/kg 5-FU every 
other day (i.p), group 3 was treated with 
90 mg/kg Losartan every day (i.p), and group 
4 received 5-FU/Losartan combination. Tu-
mor size and volume were measured every 
other day. At the end of the experiment, day 
14, tumor samples were harvested for histo-
logical staining and biochemical analysis. 
 
Table 1: qPCR primer sequences 













Col 1a1 Mouse 
Forward GGCAATGCTGAAATGTCCCA 
Reverse CCTTCAACAGTCCAAGAACCC 
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Histological assessment  
The harvested tumors were fixed, embed-
ded in paraffin, and sectioned into appropriate 
thickness (5 μm). The de-paraffinized sec-
tions were stained with hematoxylin-eosin 
(H&E) or Masson trichrome. The necrotic 




Immunohistochemistry staining for clus-
ter of differentiation 31 (CD31), used primar-
ily to identify endothelial cells, was per-
formed as described (Mirzaei et al., 2018). 
Briefly, mounted tissue sections were de-par-
affinized and re-hydrated by using xylene and 
graded alcohols, respectively. Antigen re-
trieval was achieved by boiling slides in 
Tris/EDTA for 20 min. Tissue sections were 
incubated with diluted primary (1:50) and 
secondary (1:2000) antibodies. Next, the tis-
sue sections were treated with DAB, counter-
stained with hematoxylin, and observed by 
light microscopy. 
 
Measurement of oxidative stress markers 
The production of reactive oxygen species 
(ROS) was assessed using fluorescent 2′,7′-
dichlorofluorescein diacetate (DCF-DA) ac-
cording to manufacturer’s instructions 
(Abcam, Cambridge, MA) (Negrei et al., 
2016). Catalase activity, nitric oxide (NO), 
malondialdehyde (MDA) and total thiol lev-
els were measured in tissue homogenates as 




Losartan affects various pathways related 
to progression of CRC progression 
Following treatment of the HT-29 colon 
cancer cell line, analysis of significantly up- 
or down-regulated genes extracted from the 
iLINCS database showed that Losartan af-
fects various pathways associated with tumor 
progression (using an adjusted p-value < 
0.05). These intracellular pathways included 
ERBB, epidermal growth factor receptor 
(EGFR) and Platelet-derived growth factor 
receptor (PDGFR) pathways (Figure 1A), all 
of which regulate the PI3K-AKT signaling 
axis. Assessment of changes in gene expres-
sion also showed that Losartan affects the 
genes related to control of cell cycle progres-
sion and DNA damage response in HT29 co-
lon cancer cell line. Several genes, including 
p53, BRCA1, and MYC were up-regulated 
while a number of Cyclin-dependent kinases 
were down-regulated (Figure 1A). The net-
work of protein-protein interactions showed 
that these targets formed a highly intercon-
nected network that is associated with ATR1 
through EGFR (Figure 1B). Other statistically 
enriched pathways are categorized into angi-
ogenesis and inflammation and are summa-
rized in Figure 1C, supporting Losartan’s 
therapeutic properties in treating CRC pro-
gression by regulating cancer cell prolifera-
tion, apoptosis, angiogenesis and inflamma-
tion.  
Direct gene comparisons in the high 
throughput experiments may show cell de-
pendent differences, while the altered cellular 
pathways are more robust indicators of drug 
effects on cells (Barneh et al., 2019). We thus 
used the altered pathways obtained from the 
iLINCS data analysis as a starting point and 
further validated them in our experiments us-
ing CT-26 in vitro and in vivo models.  
 
Losartan inhibits CT-26 cell viability 
The MTT assay was used to determine cy-
totoxicity of different concentrations of 
Losartan (0-1000 μM) on CRC cells. As 
shown in Figure 2A, Losartan decreased the 
CT-26 cell viability in a concentration-de-
pendent manner with an IC50 of approxi-
mately 300 μM. To further assess the cyto-
toxic effects of Losartan on CRC cells, 3-D 
cell culture spheroids were treated with 
Losartan and tumor size and shape were ana-
lyzed for a week. Consistent with 2-D cell 
culture, Losartan significantly decreased 
spheroid size and induced tumor shrinkage in 
3-D cell culture model (Figure 2B). Con-
sistent with the in silico results, Losartan up-
regulated mRNA levels of key pro-apoptotic 
EXCLI Journal 2021;20:506-521 – ISSN 1611-2156 







Figure 1: Analysis 







lowing treatment of 
HT-29 colon cancer 





analysis carried out 




sion changes within 
these pathways an-
alyzed using 
iLINCS database in 
Losartan-stimu-
lated HT-29 cells. 
The heat map 
shows the log (ex-
pression) level of 
genes in the se-
lected pathways for 
different concentra-
tions of losartan. 
(B) Gene contents 
of selected path-
ways associated 
with cell cycle were 
submitted to 
STRING v.10.5 for 
analysis of protein- 
protein interactions. 
Interactions defined 
by text-mining were 
excluded and the 
resulting network 
was visualized with 








fects of Losartan 
against CRC 
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genes including P53 and BAX in CT-26 cells 
(Figure 2C), suggesting that Losartan induces 
cell toxicity and apoptosis in CRC cells. 
To further assess the cytotoxic effects of 
Losartan on CRC cells, CT-26 cells were ex-
posed to different concentrations of Losartan 
(300, 500 μM) for 24 hours and cell cycle dis-
tribution was compared between groups. 
Losartan inhibited CRC cell progression by 
increasing percentage of G1 population from 
37 % to 49 % (Figure 2D and E). It has been 
shown that cyclinD1 regulates the transition 
of cells from G1 to S phase (Resnitzky and 
Reed, 1995; Baldin et al., 1993). Moreover, 
cyclin D1 is regulated by phosphatidylinosi-
tol-4,5-bisphosphate 3-kinase (PI3K)/AKT 
signaling pathways (Ouyang et al., 2005; Gao 
et al., 2004; Canales et al., 2017). To study the 
anti-proliferative mechanism of Losartan-me-
diated G1 arrest, we investigated the regula-
tory effect of Losartan on PI3K/AKT onco-
genic signaling axis. As shown in Figure 2F, 
in a time-dependent manner, Losartan signif-
icantly down-regulated expression of PI3K, 
AKT and their down-stream target, cyclin D1. 
These results clearly suggest that Losartan’s 
anti-tumor activity is mediated by enhancing 
apoptosis and inhibition of cell proliferation 
in CRC cells. 
 
Losartan treatment inhibits tumor growth 
of colon cancer xenograft  
To validate our in silico and cellular find-
ings, we investigated the effect of Losartan on 
tumor growth in CRC xenograft model. Con-
sistent with above mentioned results, admin-
istration of Losartan significantly decreased 
tumor growth in murine CRC model and was 
well tolerated (Figure 3A). Interestingly, the 
suppressive effect of Losartan on tumor growth 
was more potent than 5-FU, the standard CRC 
chemotherapeutic, alone and combination 
therapy of losartan/5-FU, resulting in mark-
edly greater decrease in tumor size (Figure 
3A). Similarly, comparison of tumor weight 
between the groups showed that Losartan re-
duced tumor weight but this decrease was sta-
tistically significant only if co-administered 
with 5-FU (Figure 3B). Furthermore, histo-
logical staining of tumor tissues demonstrated 
that Losartan increased tissue necrosis (Fig-
ure 3C) and inhibited tissue fibrosis in the tu-
mor xenografts (Figure 3D) as visualized by 
H&E and Masson trichrome staining, respec-
tively. The murine model results suggest that 
effects of Losartan on tumor tissue necrosis 
and fibrosis are consistent with increased CT-
26 cell toxicity, apoptosis and cell cycle inhi-
bition in CRC. 
 
Losartan inhibits CRC progression by sup-
pressing cell migration and angiogenesis 
Results extracted from the iLINCS data-
base showed that angiogenesis is the pathway 
that is consistently down-regulated by in-
creasing concentrations (1.11, 10 and 100 
µM) of Losartan (adjusted p-value < 0.05) en-
riched by down-regulation of fibroblast 
growth factor receptor 2 (FGFR2), tissue in-
hibitor of metalloproteinases 2 (TIMP2) and 
phosphatidylinositol 4,5-bisphosphate 3-ki-
nase catalytic alpha (PIK3CA) in HT-29 cells. 
Regulation of actin cytoskeleton and Rac-
MMP pathway were also enriched with 
up/down regulated genes (Figure 4A), sug-
gesting that Losartan can also regulate migra-
tion. Thus, the inhibitory effects of Losartan 
on migration and angiogenesis were evalu-
ated. Results showed that Losartan (300 µM) 
decreased CT-26 cells migration (Figure 4B) 
and inhibited the enzymatic activities of 
MMP-2 and -9, key metastatic enzymes in 
CRC cells (Figure 4C). 
Tumor vascularization plays a key role in 
the progression of a neoplasm from a local-
ized tumor to a metastatic one (Folkman, 
1971; Liotta et al., 1974). Our histological 
studies in tumor xenograft tissues showed that 
Losartan disrupts vascular development and 
morphogenesis, compared to control group 
(Figure 4D). Furthermore, expression levels 
of CD31 and NO, two pro-angiogenic factors, 
were studied in tumors and results indicated a 
significant decrease in both CD31 expression 
and NO levels in losartan-treated mice when 
compared to control (Figure 4E and F). These 
results suggest that Losartan elicits anti-tumor  
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Figure 2: Losartan inhibits CT-
26 cell proliferation and induces 
cellular apoptosis by regulating 
PI3K/AKT signaling pathway. (A) 
Inhibitory effects of Losartan (0-
1000 μM) on CT-26 cell viability. 
(B) Cytotoxic effect of Losartan 
was investigated in a 3-D 
spheroid cell culture model 
system. (C) Losartan induces 
Bax and p53 mRNA expression 
in CRC tissues compared with 
control group. (D, E) Effects of 
Losartan treatment (for 24 h) on 
cell cycle progression in CT-26 
cells. (F) Regulatory effects of 
Losartan on PI3K/AKT signaling 
pathway are determined by 
Western blotting. *P<0.05 
comparison of Losartan and 
Losartan+5FU with control group 
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Figure 3: Losartan decreased 
tumor growth, size, weight, and 
fibrosis in CRC tumor xeno-
grafts. (A, B) Effect of Losartan 
on tumor size (A) and tumor 
weight (B) is compared 
beween groups. (C, D) 
Histological staining of tumor 
tissues by H&E and Masson 
trichrom for visualizing tissue 
necrosis (C) and tissue fibrosis 
(D), respectively. ** P<0.01 
comparison of Losartan+5FU 
with control group 
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Figure 4: Losartan suppresses 
cellular migration and 
angiogenesis in CRC tissues 
samples. (A) For different 
concentrations of Losartan 
treatment in HT-29 colon cancer 
cell line, up- or down-regulated 
genes were extracted from the 
iLINCS database. Following 
pathway enrichment analysis, 
genes associated with migration 
were shown in the heatmaps. (B) 
CT-26 cells were treated with 
Losartan (300 μM) at different 
time-points and the anti-migratory 
effects of Losartan were 
measured. (C) The regulatory 
effects of Losartan on the activity 
of MMP 2,9 in CRC cells were 
investigated by zymography 
method. (D) The effects of Losar-
tan on vascular density in CRC tis-
sues were investigated using H&E 
staining. (E) CD31 positive cells 
and (F) nitrite levels are signifi-
cantly decreased in losartan-
treated mice, when compared to 
the control group. *** P<0.001 
comparison of 5-FU, Losartan and 
Losartan+5FU with control group 
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effects at least partially by inhibiting migra-
tion and angiogenesis in colon cancer cells. 
 
The effects of Losartan on oxidant/ 
antioxidant balance and inflammation 
Next, we investigated the effects of Losar-
tan on inflammation by measuring oxi-
dant/antioxidant balance in tissue homoge-
nates. We showed that in tumor tissues Losar-
tan decreased thiol concentrations and cata-
lase activity, two anti-oxidant markers (Fig-
ure 5A and B), and increased MDA level and 
ROS generation, biomarkers of oxidative 
stress (Figure 5C and D). Further studies 
showed that the effect of 5-FU on oxidant/ 
anti-oxidant balance was the same as Losartan 
and co-administration of losartan/5-FU elic-
ited an additive effect in regulating oxidative 
stress in tumor tissue homogenates.  
To further identify the regulatory effects 
of Losartan on cellular pro-inflammatory re-
sponses, we evaluated the expression of pro-
inflammatory molecules in losartan-stimu-
lated CRC cells. Our results showed that 
Losartan treatment significantly increased the 
expression of IL-1β, TNF-α, and MCP-1 
compared to the control group (Figure 5E). 
These data suggest that the anti-tumor activity 
of Losartan against colon cancer cells may be 
mediated by disruption of the oxidant/antiox-
idant balance as well as up-regulation of pro-
inflammatory cytokines, leading to increased 
cancer cell death. 
 
DISCUSSION 
The renin-angiotensin system plays an 
important role in cancer progression in differ-
ent malignancies. In this study, we integrated 
systems and molecular biology to investigate 
the mechanisms of the anti-tumor effects of 
Losartan in CRC progression in cellular and 
animal models. Our results showed that 
Losartan elicits potent anti-tumor properties 
by inhibiting cell proliferation, migration, in-
flammation, and angiogenesis while increas-
ing apoptosis in CRC. 
Aberrant activation of renin-angiotensin 
system is found in different malignancies and 
is associated with tumor metastasis, invasion, 
migration, and angiogenesis (Ager et al., 
2008; Suganuma et al., 2005; Juillerat-
Jeanneret et al., 2004; Kikkawa et al., 2004; 
Dinh et al., 2001). The activated form of 
AT1R triggers the Ras/PI3K/AKT/mTOR 
axis, a key proliferative signaling pathway in 
tumors (Baldus et al., 2010; Du et al., 2012). 
Li et al. have also shown that the inhibition of 
AT1R significantly decreased AKT activa-
tion whereas Angiotensin II up-regulated 
mTOR in esophageal carcinoma cells (Li et 
al., 2016). Cyclin D1, a key downstream tar-
get of PI3K/AKT/ mTOR signaling, is over-
expressed in several human cancers including 
CRC (Rahmani et al., 2018; Arqués et al., 
2016). Cyclin D1 is a regulatory subunit for 
cyclin-dependent kinases including CDK4 
and plays a prominent role in cell cycle pro-
gression from G1 to S phase (Peurala et al., 
2013). In the current study, we explored 
whether proliferative effects of angiotensin 
on CRC cells can be suppressed by Losartan 
by investigating downstream targets of Angi-
otensin/AT1R signaling, such as PI3K/AKT/ 
mTOR pathway activity and cyclin D1 ex-
pression. Our findings indicate that Losartan 
treatment inhibits PI3K/AKT signaling as vis-
ualized by down-regulation of PI3K and Cy-
clin D1 protein levels and inhibition of AKT 
phosphorylation. 
Further studies showed that activation of 
PI3K/AKT signaling correlates with cancer 
cell apoptosis (Brader and Eccles, 2004; 
Osaki et al., 2004). AKT inhibited apoptosis 
through the phosphorylation of pro-apoptotic 
proteins (Cardone et al., 1998; Datta et al., 
1997). Zhao et al. showed that Losartan in-
duced apoptosis through the inhibition of 
PI3K/ AKT pathway in MCF-7 cell line 
(Zhao et al., 2008). P53 and BAX are key pro-
apoptotic regulators in apoptosis process 
(Ruvolo et al., 2001; Li et al., 2009). Further-
more, Ahmadian el al. demonstrated that 
Azilsartan, an AT1R antagonist, elevated 
apoptosis at least partially by increasing BAX 
mRNA expression in HepG2 hepatocellular 
carcinoma cells (Ahmadian et al., 2018a). 
Moreover, Koh et al. showed that RAS inhib-
itors induced apoptosis in colorectal cancer 
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Figure 5: Losartan induces cellular 
oxidative stress and inflammatory 
responses in CRC tissues. (A) The 
regulatory effect of Losartan on total 
thiol concentrations was measured 
in tissue homogenates. (B) The 
same as A except that catalase ac-
tivity was measured. (C) The same 
as A except that MDA level was 
compared between groups. (D) 
Losartan significantly induces cellu-
lar oxidative stress in CT-26 cells. 
(E) mRNA levels of pro-inflamma-
tory cytokines were investigated by 
q-PCR in CRC tissues. * P<0.05, ** 
P<0.01 and *** P<0.001 comparison 
of 5-FU, Losartan and 
Losartan+5FU with control group, 
### P<0.001 comparison of 
Losartan+5FU with 5-FU group, +++ 
P<0.001 comparison of Losartan+ 
5FU with Losartan group 
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liver metastases (Koh et al., 2014). In agree-
ment with these results, we demonstrated that 
Losartan induces apoptosis by inhibition of 
the PI3K/AKT pathway and elevation of p53 
and BAX levels in CRC.  
We also evaluated the anti-tumor effects 
of Losartan in a mouse model of colon cancer. 
Our results indicated that Losartan decreased 
tumor growth by inhibiting angiogenesis and 
changing the oxidant/anti-oxidant balance in 
tumor tissue. There is evidence that renin-an-
giotensin system inhibitors suppress tumor 
angiogenesis by reducing vascular endothe-
lial growth factor expression and altering the 
tumor microenvironment (Greene and 
Amaral, 2002; Kubota et al., 2011). Similarly, 
Valuckaite et al. showed that Losartan de-
creased angiogenesis by reducing VEGF pro-
tein levels and VEGF expression in AOM in-
duced colorectal cancer (Valuckaite et al., 
2015). Neo et al. have shown that renin-angi-
otensin system blockers, captopril and 
irbesartan, significantly decreased tumor 
growth in colorectal cancer liver metastases 
which was correlated with reduced central mi-
crovascular density (Neo et al., 2007). In line 
with these findings Koh et al. demonstrated 
that captopril, a renin-angiotensin blocker, 
decreased angiogenesis by reducing CD-34-
positive vessels in CRC liver metastases (Koh 
et al., 2014). Our histological studies in tumor 
xenograft tissues showed that Losartan dis-
rupts vascular development and morphogene-
sis, and down-regulates levels of CD31 and 
NO, two pro-angiogenic factors, when com-
pared to the control group.  
There is some evidence that the current 
drugs used for cancer treatment affect oxida-
tive stress. ROS production has an important 
role in apoptosis induction and reduction of 
cell viability in early stages of cancer (Negrei 
et al., 2016; Eftekhari et al., 2018). Further-
more, elevation of ROS leads to changing of 
mitochondrial permeability transition pore 
and elevation of cytochrome C-induced apop-
tosis (Ahmadian et al., 2018b, 2016). Ahmad-
ian et al. demonstrated that azilsartan induced 
ROS formation in HepG2 hepatocellular car-
cinoma cells (Ahmadian et al., 2018a). Re-
sults of our study showed that administration 
of Losartan increased MDA levels and re-
duced total thiol concentration and catalase 
activity. These results suggest that alterations 
of the oxidant-antioxidant status can be one of 
the underlying mechanisms in Losartan anti-
tumor activities against colon cancer cells.  
Taken together, we have shown that 
Losartan elicits its anti-tumor properties by 
inhibiting CRC cell growth, cell cycle pro-
gression, reducing angiogenesis and attenuat-
ing migration. In addition, it enhances tumor 
cell necrosis, elevating inflammatory re-
sponses, altering oxidant/anti-oxidant bal-
ance, and inducing apoptosis. Combination of 
Losartan and 5-FU revealed synergistic and 
additive anti-tumorigenic properties, suggest-
ing that targeting of the renin-angiotensin sys-
tem presents a potentially new therapeutic 
strategy in colon cancer treatment. 
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